Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.

A randomized controlled non-inferiority study comparing the antiemetic effect between intravenous granisetron and oral azasetron based on estimated 5-HT3 receptor occupancy.

Endo J, Iihara H, Yamada M, Yanase K, Kamiya F, Ito F, Funaguchi N, Ohno Y, Minatoguchi S, Itoh Y.

Anticancer Res. 2012 Sep;32(9):3939-47.

PMID:
22993341
2.

[Analysis of antiemetic effect of various dosage regimens of azasetron hydrochloride based on 5-HT3 receptor occupancy of serotonin].

Yamada Y, Fujita M, Okuyama K, Takayanagi R, Ozeki T, Yokoyama H, Iga T.

Yakugaku Zasshi. 2007 Feb;127(2):353-7. Japanese.

3.

Theoretical evaluation of antiemetic effects of 5-HT3 receptor antagonists for prevention of vomiting induced by cisplatin.

Nakamura H, Yokoyama H, Takayanagi R, Yoshimoto K, Nakajima A, Okuyama K, Iwase O, Yamada Y.

Eur J Drug Metab Pharmacokinet. 2015 Mar;40(1):39-44. doi: 10.1007/s13318-014-0175-z. Epub 2014 Jan 28.

PMID:
24470169
4.

[Pharmacokinetics of azasetron (Serotone), a selective 5-HT3 receptor antagonist].

Tsukagoshi S.

Gan To Kagaku Ryoho. 1999 Jun;26(7):1001-8. Japanese.

PMID:
10396331
5.

Receptor occupancy theory-based analysis of interindividual differences in antiemetic effects of 5-HT3 receptor antagonists.

Ayuhara H, Takayanagi R, Okuyama K, Yoshimoto K, Ozeki T, Yokoyama H, Yamada Y.

Int J Clin Oncol. 2009 Dec;14(6):518-24. doi: 10.1007/s10147-009-0912-5. Epub 2009 Dec 5.

PMID:
19967488
6.

Absorption characteristics of azasetron from rectal and oral routes in rabbits.

Moriyama Y, Arimori K, Nakano M.

Biol Pharm Bull. 1997 Jun;20(6):701-3.

PMID:
9212995
8.

Method for individualized evaluation of antiemetic effect induced by 5-HT3 receptor antagonist.

Nakamura H, Yokoyama H, Yoshimoto K, Nakajima A, Okuyama K, Iwase O, Yamada Y.

Biol Pharm Bull. 2013;36(5):780-7. Epub 2013 Mar 4.

9.
10.
11.

[A randomized crossover comparison of azasetron and granisetron in the prophylaxis of emesis induced by chemotherapy including cisplatin].

Tsukuda M, Mochimatsu I, Furukawa M, Kohno H, Kawai S, Enomoto H, Yago T, Matsuda H, Ikema Y, Zhou L.

Gan To Kagaku Ryoho. 1995 Nov;22(13):1959-67. Japanese.

PMID:
7487127
12.

Randomized crossover pharmacokinetic evaluation of subcutaneous versus intravenous granisetron in cancer patients treated with platinum-based chemotherapy.

Gurpide A, Sadaba B, Martin-Algarra S, Azanza JR, Lopez-Picazo JM, Campanero MA, Cabello JP, Gil-Aldea I, de la Cruz S, Fernandez Gallego V, Reyna C, Olier Garate C, Blanco-Prieto MJ, Ceballos J, Garcia-Foncillas J, Perez-Gracia JL.

Oncologist. 2007 Sep;12(9):1151-5.

13.

[A randomized crossover comparison of azasetron alone and azasetron plus dexamethasone for the prevention of nausea and vomiting by chemotherapy including cisplatin].

Fujii M, Kanke M, Arai Y, Kawai S, Enomoto H, Inaba H, Taguchi T, Tsukuda M.

Gan To Kagaku Ryoho. 2000 Sep;27(10):1557-63. Japanese.

PMID:
11016001
14.

[Study on clinical effect of a continuous intravenous infusion of azasetron against nausea and vomiting induced by anticancer drugs including CDDP].

Kimura E, Niimi S, Watanabe A, Akiyama M, Tanaka T.

Gan To Kagaku Ryoho. 1996 Mar;23(4):477-81. Japanese.

PMID:
8678501
15.

Electrocardiographic findings after 5-HT3 receptor antagonists and chemotherapy in children with cancer.

Pinarli FG, Elli M, Dagdemir A, Baysal K, Acar S.

Pediatr Blood Cancer. 2006 Oct 15;47(5):567-71.

PMID:
16317736
16.

Formulation and in vitro/in vivo correlation of a drug-in-adhesive transdermal patch containing azasetron.

Sun L, Cun D, Yuan B, Cui H, Xi H, Mu L, Chen Y, Liu C, Wang Z, Fang L.

J Pharm Sci. 2012 Dec;101(12):4540-8. doi: 10.1002/jps.23317. Epub 2012 Sep 12.

PMID:
22972714
17.
18.

Low-dose oral granisetron (1 mg) plus intravenous dexamethasone: efficacy in gynecologic cancer patients receiving carboplatin-based chemotherapy.

Markman M, Kennedy A, Webster K, Kulp B, Peterson G, Belinson J.

Gynecol Oncol. 1998 Oct;71(1):113-5.

PMID:
9784330
19.

Randomized controlled study comparing two doses of intravenous granisetron (1 and 3 mg) for acute chemotherapy-induced nausea and vomiting in cancer patients: a non-inferiority trial.

Yonemura M, Katsumata N, Hashimoto H, Satake S, Kaneko M, Kobayashi Y, Takashima A, Kato Y, Takeuchi M, Fujiwara Y, Yamamoto H, Hojo T.

Jpn J Clin Oncol. 2009 Jul;39(7):443-8. doi: 10.1093/jjco/hyp036. Epub 2009 Apr 24.

PMID:
19395466

Supplemental Content

Support Center